Innovent Reports the Result Of Mazdutide (IBI362) in the P-II Study on Chinese Patients with Type-2 Diabetes (T2D)
Shots:
- The P-II study evaluating the safety & efficacy of Mazdutide vs PBO in Chinese patients (n=252) with T2D randomized to receive 3mg, 4.5mg, 6mg mazdutide & 1.5mg open-label dulaglutide/PBO for 20wks.
- The result of the study depicted a change from the mean baseline to week 20 in HbA1c levels were -1.41%, -1.67% -1.55% & -1.35%/0.03%.Additionally the percentage of patients with HbA1c ＜7.0% were 54.0%, 66.7%, 73.5% & 60%/17.6%; with HbA1c ≤6.5% were 28.0%, 56.3%, 51.0%, 46%/7.8%.
- Furthermore, the mean percent change from baseline to week 20 in body wt. were -4.12%, -5.31%, -7.11% &-2.69/-1.38. The percentage of body wt. loss of ≥5% were 24.0%, 37.5%,57.1% & 18%/9.8%, and 16%, 29.2%, 49%, & 12%/0 achieved body wt. loss of ≥5% and HbA1c of <7.0%
Ref: PRNewswire | Image: Innovent
Related News:- Innovent Reports P-II Clinical Trial Results of Mazdutide (IBI362) for the Treatment of Obesity in Chinese Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
